FLORHAM PARK, N.J., September 07, 2023 Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), announced the upcoming presentation of new data at IDWeek 2023 (October 11-15, 2023) on its investigational oral antiviral for COVID-19, ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.: S-217622, hereafter "ensitrelvir"), and Fetroja® (cefiderocol), an antibiotic marketed under the brand name Fetcro
Shionogi USA: IDWeek 2023: Shionogi and Qpex Biopharma, Inc Continue Longstanding Commitment to Addressing Unmet Needs in Infectious Disease finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve.
A new antibiotic that treats gram-negative bacteria has just passed Phase I clinical trials with ease, bringing a new tool to fight antibiotic resistance.
Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.